Cancer Letters
Volume 299, Issue 1 , Pages 72-79 , 18 December 2010

Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells

  • Alfredo Toschi

      Affiliations

    • Department of Biological Sciences, Hunter College of the City University of New York, NY 10021, USA
    • Present address: New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, United States.
    • ,
  • Evan Lee

      Affiliations

    • Department of Biological Sciences, Hunter College of the City University of New York, NY 10021, USA
    • ,
  • Sebastian Thompson

      Affiliations

    • Department of Chemistry, Hunter College of the City University of New York, NY 10021, USA
    • ,
  • Noga Gadir

      Affiliations

    • Department of Biological Sciences, Hunter College of the City University of New York, NY 10021, USA
    • Present address: Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel.
    • ,
  • Paige Yellen

      Affiliations

    • Department of Biological Sciences, Hunter College of the City University of New York, NY 10021, USA
    • ,
  • C. Michael Drain

      Affiliations

    • Department of Chemistry, Hunter College of the City University of New York, NY 10021, USA
    • ,
  • Michael Ohh

      Affiliations

    • Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Ontario, Canada M5S 1A8
    • ,
  • David A. Foster

      Affiliations

    • Department of Biological Sciences, Hunter College of the City University of New York, NY 10021, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 772 4075; fax: +1 212 772 5227.

Received 16 June 2010 ,Revised 14 July 2010 ,Accepted 9 August 2010.

References 

  1. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20
  2. Warburg O. On the origin of cancer cells. Science. 1956;123:309–314
  3. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–270
  4. DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 2008;18:54–61
  5. Hickey MM, Simon MC. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr. Top. Dev. Biol. 2006;76:217–257
  6. Gordan JD, Simon MC MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr. Opin. Genet. Dev. 2007;17:71–77
  7. Toschi A, Edelstein J, Rockwell P, Ohh M, Foster DA. Elevated HIF2 expression in VHL deficient renal cell carcinoma cells is dependent on phospholipase D. Oncogene. 2008;27:2746–2753
  8. Zheng Y, Rodrik V, Toschi A, Shi M, Hui L, Shen Y, et al. Phospholipase D couples survival and migration signals in response to stress in human breast cancer cells. J. Biol. Chem. 2006;281:15862–15868
  9. Chen Y, Rodrik V, Foster DA. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene. 2005;24:672–679
  10. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001;294:1942–1945
  11. Veverka V, Crabbe T, Bird I, Lennie G, Muskett FW, Taylor RJ, et al. Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene. 2008;27:585–595
  12. Foster DA. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochem. Biophys. Acta. 2009;1791:949–955
  13. Sawyers CL. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell. 2003;4:343–348
  14. Foster DA. Targeting mTOR-mediated survival signals in anticancer therapeutic strategies. Exp. Rev. Anticancer Therapy. 2004;4:691–701
  15. Kim WY, Kaelin WG. Molecular pathways in renal cell carcinoma-rationale for targeted treatment. Semin. Oncol. 2006;88–95
  16. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484
  17. Laplante M, Sabatini DM. MTOR signaling at a glance. J. Cell Sci. 2009;122:3589–3594
  18. Sung TC, Altshuller YM, Morris AJ, Frohman MA. Differential dependence of HIF1 and HIF2 on mTORC1 and mTORC2. J. Biol. Chem. 1999;274:494–502
  19. Sung TC, Roper RL, Zhang Y, Rudge SA, Temel R, Hammond SM, et al. Molecular analysis of mammalian phospholipase D2. EMBO J. 1997;16:4519–4530
  20. Shen AY, Xu L, Foster DA. Phospholipase D requirement for receptor-mediated endocytosis. Mol. Cell. Biol. 2001;21:595–602
  21. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid – a competition with rapamycin. Mol. Cell. Biol. 2009;29:1411–1420
  22. Chen Y, Zheng Y, Foster DA. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene. 2003;22:3937–3942
  23. Zhong M, Joseph T, Jackson D, Beychenok S, Foster DA. Elevated phospholipase D induces apoptosis in normal rat fibroblasts. Biochem. Biophys. Res. Commun. 2002;298:474–477
  24. Ohh M. Ubiquitin pathway in VHL cancer syndrome. Neoplasia. 2006;8:623–629
  25. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 1998;18:732–741
  26. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell. 1998;1:959–968
  27. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43–54
  28. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3:177–185
  29. Bui T, Thompson CB. Cancer’s sweet tooth. Cancer Cell. 2006;9:419–420
  30. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22
  31. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Defining the role of mTOR in cancer. Science. 2005;307:1098–1101
  32. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892–3899
  33. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–1274
  34. Dummler B, Hemmings BA. Physiological roles of PKB/Akt isoforms in development and disease. Biochem. Soc. Trans. 2007;35:231–235
  35. López-Lázaro M. Does hypoxia really control tumor growth?. Cell. Oncol. 2006;28:327–329
  36. López-Lázaro M. The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?. Anticancer Agents Med. Chem. 2008;8:305–312
  37. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–1033
  38. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9:425–434
  39. Kondo K, Kim WY, Lechpammer M, Kaelin WG. Inhibition of HIF2 is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003;1:439–444
  40. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13:472–482
  41. López-Lázaro M. A new view of carcinogenesis and an alternative approach to cancer therapy. Mol. Med. 2010;16:144–153

PII: S0304-3835(10)00387-3

doi: 10.1016/j.canlet.2010.08.006

Cancer Letters
Volume 299, Issue 1 , Pages 72-79 , 18 December 2010

Article Tools

* Image Usage & Resolution